Compare Hilton Hotels Corporation Common Stock (HLT) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Eli Lilly And Co — how do they compare? Hilton Hotels Corporation Common Stock trades at $327.15 (market cap $72.76B), while Eli Lilly And Co trades at $1,177 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 14.3× Hilton Hotels Corporation Common Stock's market cap, and Eli Lilly And Co pays the higher dividend (0.59%). Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Eli Lilly And Co for 93 Days on average.
| HLT | LLY | |
|---|---|---|
Market Cap | $72.76B | $1.04T |
Volume | 1,148,634 | 3,064,878 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $1.28K |
52-Week Low | $256.96 | $799.57 |
Typical Hold Time | 138 Days | 93 Days |
Enterprise Value | $85.78B | $1.09T |
Dividend Yield | 0.19% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $327.48, up 2.18% today, reflecting strong momentum near its recent highs. The stock shows a bullish technical setup with consistent earnings beats in recent quarters and solid revenue growth, with 2025 revenue reaching $12.04 billion. Analyst sentiment is positive, with a consensus price target of $348.11 and no sell ratings among 49 analysts. Recent news highlights institutional buying and the upcoming Q3 2026 earnings report on October 27, 2026.
The outlook for HLT remains favorable, driven by robust travel demand, global portfolio expansion, and strong operational cash flow. Key risks include high debt levels, with a debt-to-asset ratio rising to 73.88% in 2025, and sensitivity to economic cycles. Upside potential hinges on continued execution and market share gains in high-growth regions like Asia, as noted in recent company reports.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
